Clinical trials: GENE EXPRESSION
Non-Small Cell Lung Cancer
A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer
Thymidylate synthase (TS) is a substance the body produces naturally. The purpose of this research is to determine if there is a link between TS production and how well patients respond to treatment of non-squamous non-small cell…
- Trial name
- NCT00887549
- Testing
- pemetrexed, cisplatin
- Where
- 14 sites in Ireland, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor…
- Trial name
- NCT03631706
- Testing
- M7824, Pembrolizumab
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 304 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
High-grade Glioma, Lung Cancer
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
This proof-of-concept study is designed to assess the ability of [18F]AH-111585 PET imaging to detect tumors and angiogenesis. Up to 30 evaluable subjects are planned to be included at up to 2 study centers in the US.
- Conditions
- High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma
- Trial name
- NCT00565721
- Testing
- Fluciclatide Injection - (AH111585 (F18))
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- GE Healthcare
Actinic Keratosis
Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT)
The aim of this study is to determine possible molecular changes on large scale gene expression profiling after treatment with Metvix photodynamic therapy (PDT) of actinic keratoses (AK) and cancerised field in renal transplant…
- Trial name
- NCT01000636
- Testing
- Metvix PDT
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Galderma R&D
Neoplasms, Solid Tumors
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available…
- Conditions
- Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer
- Trial name
- NCT02091141
- Testing
- Trastuzumab, Pertuzumab, Erlotinib
- Where
- 60 sites in United States
- Volunteers
- 673 people
- Sponsor
- Genentech, Inc.
Ovarian Cancer
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer.
- Trial name
- NCT01684878
- Testing
- Gemcitabine (Chemotherapy), Paclitaxel (Chemotherapy), Pertuzumab
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Non - Small Cell Lung Cancer NSCLC
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of…
- Trial name
- ARCTIC (NCT02352948)
- Testing
- MEDI4736 (durvalumab), Vinorelbine, Gemcitabine
- Where
- 201 sites in United States, Australia and 24 more
- Volunteers
- 597 people
- Sponsor
- AstraZeneca
Gene Expression
Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler
To compare gene expression stimulated by a semi-permanent filler and a biostimulator via punch biopsy
- Trial name
- Sculptra (NCT05620043)
- Testing
- Sculptra, Radiesse Plus
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Dry Eye Syndrome
SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers
The purpose of this study is to evaluate the ability of SYSTANE® BALANCE and SYSTANE® Gel to improve comfort in subjects with dry eyes.
- Trial name
- NCT01733732
- Testing
- SYSTANE® BALANCE Lubricant Eye Drops, SYSTANE® Gel
- Volunteers
- 54 people
- Sponsor
- Alcon Research
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- SORAYA (NCT04296890)
- Testing
- Mirvetuximab Soravtansine
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- ImmunoGen, Inc.
Myelodysplastic Syndrome
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Several previous studies (clinical and non-clinical) hypothesize that treatment with deferasirox causes a hematological improvement in transfused patients with low and intermediate-1 risk myelodysplastic syndrome.
- Trial name
- EXPHAR (NCT02663752)
- Testing
- Bone marrow aspirate, Deferasirox
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Non-Small Cell
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
This study intends to analyze the expression of specific sets of markers in tumor samples and in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma.
- Trial name
- NCT00685750
- Testing
- Collection of tumor and blood samples
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 88 people
- Sponsor
- GlaxoSmithKline
Leukemia, Acute Myeloid, Myelodysplastic Syndrome
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
The primary objective of this study is to evaluate the safety, tolerability, and efficacy of temozolomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) participants who are not candidates for standard…
- Trial name
- TALL (NCT00687323)
- Testing
- temozolomide
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma (HCC), Solid Malignancies
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid…
- Trial name
- NCT02325739
- Testing
- FGF401, PDR001
- Where
- 27 sites in United States, China and 9 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Unresectable or Metastatic Solid Malignancy
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced…
- Trial name
- MyTACTIC (NCT04632992)
- Testing
- Entrectinib, Inavolisib, Alectinib
- Where
- 38 sites in United States
- Volunteers
- 252 people
- Sponsor
- Genentech, Inc.
Alpha-1 Antitrypsin Deficiency (AATD)
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
This study is the first study in the RestorAATion clinical program. The purpose of this first-in human (FIH), double-blind, randomized, placebo-controlled, single ascending dose (SAD) and multiple-dose Phase 1 study is to assess…
- Trial name
- RestorAATion-1 (NCT06186492)
- Testing
- WVE-006
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wave Life Sciences USA, Inc.
Non-squamous Non-small Cell Lung Cancer
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
This is an open label single group, Phase 2, 1-arm study for treatment to evaluate efficacy, safety, and Pharmacokinetic (PK) of tusamitamab ravtansine in nonsquamous non-small-cell-lung-cancer (NSQ NSCLC) participants with…
- Trial name
- CARMEN-LC06 (NCT05245071)
- Testing
- Tusamitamab ravtansine
- Where
- 35 sites in United States, Belgium and 5 more
- Volunteers
- 22 people
- Sponsor
- Sanofi
Ovarian Cancer, NSCLC
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
The purpose of this study was to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab.
- Conditions
- Ovarian Cancer, NSCLC, ESCC, Solid Tumors
- Trial name
- NCT04939701
- Testing
- ASP0739
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Chest Pain, Cardiovascular Diseases
PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis
This is a prospective, multi-center study examining the clinical impact of the Corus CAD (Age/Sex/Gene Expression score - ASGES) assay in approximately 250 evaluable subjects with no history of obstructive coronary artery disease…
- Conditions
- Chest Pain, Cardiovascular Diseases, Angina Pectoris, Coronary Artery Disease
- Trial name
- IMPACT-PCP (NCT01594411)
- Testing
- Corus CAD
- Where
- 4 sites in United States
- Volunteers
- 251 people
- Sponsor
- CardioDx
Rheumatoid Arthritis
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at baseline will relieve signs and symptoms of the disease.
- Trial name
- NCT01034306
- Testing
- CF101
- Where
- 5 sites in Bulgaria, Israel
- Volunteers
- 79 people
- Sponsor
- Can-Fite BioPharma